GILD
NasdaqGILEAD SCIENCES, INC.
Basic Materials · Biological Products, (No Diagnostic Substances)
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$27.3B
2021
$27.3B
2022
$27.1B
2023
$28.8B
2024
$29.4B
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$29.4B
Net Income$8.5B
Gross Profit—
Oper Income$10.0B
EPS (dil)$6.78
Rev/sh$23.71
FCF/sh$7.62
Book/sh$18.22
Gross M—
Oper M34.0%
Profit M28.9%
FCF M32.1%
ROE37.6%
ROA14.4%
ROIC20.3%
R&D/Rev30.9%
Rev Y/Y2.4%
Rev 3Y CAGR2.6%
EPS Y/Y1684.2%
EPS 3Y CAGR23.0%
FCF 3Y CAGR4.3%
Payout47%
Div/sh$3.16
Shs Chg Y/Y0%
Current Ratio1.55
Quick Ratio1.40
Debt/Eq1.23
Int Coverage9.8×
Net Debt$20.2B
Total Debt$27.7B
Cash & Eq$7.6B
Total Assets$59.0B
Oper CF$10.0B
Capex$563.0M
Free CF$9.5B
Buybacks$1.9B
Equity$22.6B
Liabilities—
Shs Outstand1.24B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $27.3B | $27.3B | $27.1B | $28.8B | $29.4B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $9.9B | $7.3B | $7.6B | $1.7B | $10.0B |
| Net Income | $6.2B | $4.6B | $5.6B | $480.0M | $8.5B |
| Diluted EPS | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 |
| Operating Cash Flow | $11.4B | $9.1B | $8.0B | $10.8B | $10.0B |
| Free Cash Flow | $10.8B | $8.3B | $7.4B | $10.3B | $9.5B |
COMMUNITY · $GILD0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.